Your browser doesn't support javascript.
loading
Insights from early experience of a Rare Disease Genomic Medicine Multidisciplinary Team: a qualitative study.
Ormondroyd, Elizabeth; Mackley, Michael P; Blair, Edward; Craft, Jude; Knight, Julian C; Taylor, John; Taylor, Jenny C; Wilkie, Andrew Om; Watkins, Hugh.
Afiliação
  • Ormondroyd E; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Mackley MP; National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford, UK.
  • Blair E; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Craft J; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Knight JC; National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford, UK.
  • Taylor J; Department of Clinical Genetics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Taylor JC; Oxford NHS Regional Molecular Genetics Laboratory, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Wilkie AO; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Watkins H; Oxford NHS Regional Molecular Genetics Laboratory, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Eur J Hum Genet ; 25(6): 680-686, 2017 06.
Article em En | MEDLINE | ID: mdl-28327571
ABSTRACT
Whole-exome/whole-genome sequencing (WES/WGS) has the potential to enhance genetic diagnosis of rare disease, and is increasingly becoming part of routine clinical care in mainstream medicine. Effective translation will require ongoing efforts in a number of areas including selection of appropriate patients, provision of effective consent, pre- and post-test genetic counselling, improving variant interpretation algorithms and practices, and management of secondary findings including those found incidentally and those actively sought. Allied to this is the need for an effective education programme for all members of clinical teams involved in care of patients with rare disease, as well as to maintain public confidence in the use of these technologies. We established a Genomic Medicine Multidisciplinary Team (GM-MDT) in 2014 to build on the experiences of earlier successful research-based WES/WGS studies, to address these needs and to review results including pertinent and secondary findings. Here we report on a qualitative study of decision-making in the GM-MDT combined with analysis of semi-structured interviews with GM-MDT members. Study findings show that members appreciate the clinical and scientific diversity of the GM-MDT and value it for education and oversight. To date, discussions have focussed on case selection including the extent and interpretation of clinical and family history information required to establish likely monogenic aetiology and inheritance model. Achieving a balance between effective use of WES/WGS - prioritising cases in a diverse and highly complex patient population where WES/WGS will be tractable - and meeting the recruitment targets of a large project is considered challenging.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Equipe de Assistência ao Paciente / Testes Genéticos / Doenças Raras / Genética Médica / Doenças Genéticas Inatas Tipo de estudo: Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Equipe de Assistência ao Paciente / Testes Genéticos / Doenças Raras / Genética Médica / Doenças Genéticas Inatas Tipo de estudo: Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article